Pfizer’s Ibrance breast cancer drug combo fails to improve OS in phase 3 trial

This article was originally published here

Pfizer said that its breast cancer drug Ibrance (palbociclib) in combination with fulvestrant was not statistical significant in extending overall survival (OS) in a phase 3 Paloma-3 trial.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply